AMLX Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 2.77
- PEG ratio
- —
- P/B
- 15.72
- P/S (TTM)
- 0.66
- EV/EBITDA
- -11.71
Profitability & growth
- ROE (TTM)
- -74.7%
- Operating margin
- 0.0%
- Revenue growth YoY
- -99.6%
- Dividend yield
- —
- Beta
- -0.20
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Amylyx Pharmaceuticals Inc
Company profileAmylyx Pharmaceuticals Inc (AMLX) is an innovative biopharmaceutical company at the forefront of developing transformative therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). The company's lead candidate, AMX0035, employs a unique neuroprotective mechanism that has shown significant potential in improving patient outcomes in clinical trials. With a robust pipeline and a dedicated team of neurology experts, Amylyx is well-positioned to tackle substantial unmet medical needs in the neurodegenerative space, making it an attractive investment opportunity…
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
